Aldeyra Therapeutics Inc is a biotechnology company operating in the US. It focuses on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. The company is developing ADX-102 as well as other novel product candidates, including ADX-103 and ADX-104, which are designed specifically to sequester aldehydes for the treatment Noninfectious Anterior Uveitis, Allergic Conjunctivitis, Dry Eye Syndrome and other. The company operates through the single segment being, the Identification, and development of a treatment for diseases related to high levels of aldehydes.